- 全部删除
- 您的购物车当前为空
Melanoma is a lethal skin cancer. The early detection of melanoma using positron emission tomography (PET) probes is critical for improving the survival of melanoma patients. Melanin probe-2 is a non-radioactive bromo-picolinamide precursor that has been used for the synthesis of18F-picolinamides based PET probe (melanin probe-1). The tumor-targeting efficacy and imaging property of three melanin probes were evaluated in B16F10 tumor-bearing mice.18F-1 and18F-3 had much lower tumor uptake compared with18F-2 (Melanin probe-2), which were 12.74 ± 1.70, 16.61 ± 2.60, and 16.87 ± 1.23 %ID/g at 0.5, 1, and 2 h, respectively[1].
Melanoma is a lethal skin cancer. The early detection of melanoma using positron emission tomography (PET) probes is critical for improving the survival of melanoma patients. Melanin probe-2 is a non-radioactive bromo-picolinamide precursor that has been used for the synthesis of18F-picolinamides based PET probe (melanin probe-1). The tumor-targeting efficacy and imaging property of three melanin probes were evaluated in B16F10 tumor-bearing mice.18F-1 and18F-3 had much lower tumor uptake compared with18F-2 (Melanin probe-2), which were 12.74 ± 1.70, 16.61 ± 2.60, and 16.87 ± 1.23 %ID/g at 0.5, 1, and 2 h, respectively[1].
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 mg | ¥ 7,552 | 5日内发货 |
产品描述 | Melanoma is a lethal skin cancer. The early detection of melanoma using positron emission tomography (PET) probes is critical for improving the survival of melanoma patients. Melanin probe-2 is a non-radioactive bromo-picolinamide precursor that has been used for the synthesis of18F-picolinamides based PET probe (melanin probe-1). The tumor-targeting efficacy and imaging property of three melanin probes were evaluated in B16F10 tumor-bearing mice.18F-1 and18F-3 had much lower tumor uptake compared with18F-2 (Melanin probe-2), which were 12.74 ± 1.70, 16.61 ± 2.60, and 16.87 ± 1.23 %ID/g at 0.5, 1, and 2 h, respectively[1]. |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容